Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 28;10(7):268. doi: 10.3390/metabo10070268

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Cholinic phenotype is impacted by doxorubicin treatment in ovo. The boxplots present the alteration for glycerophospholipid metabolism triggered after the treatment of in ovo tumors with doxorubicin. (A) Choline level is not affected by doxorubicin treatment. (B) Cytidine 5’−diphosphocholine, (C) phosphatidylcholines (e.g., PC(18:1/20:2)), (D) Phosphoethanolamine, (E) Cytidine−5’−diphosphoethanolamine, (F) Phosphoethanolamines (e.g., PE(18:1/20:2)), (G) Dihomo−linoleate (20:2n6), (H) Oleoylcarnitine (C18:1), (I) Glycerophosphorylcholine, and (J) Glycerophosphoethanolamine show nominally significant alterations after the treatment. Vehicle-treated tumors (VEH) are depicted in grey, and those treated with doxorubicin (DOX) are indicated in red.